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EDITORIAL REVIEW
Pathophysiology of low renin syndromes: Sites of renal renin
secretory impairment and prorenin overexpression
The renin-angiotensin-aldosterone system (RAAS) plays an
important role in cardiovascular and electrolyte regulation in
health and disease [1—3]. Although peripherally produced renin
plays a role, renin secretion (RS) from juxtaglomerular (JO)
cells initiates the endocrine cascade by cleaving angiotensin I
from a precursor molecule which in turn generates angiotensin
II (Ang II) to complete the physiologic cycle by stimulating
vascular smooth muscle contraction and aldosterone secretion
and by inhibiting RS, probably through an exaggerated negative
feedback hyporesponsivity involving Ca. Renal RS is modu-
lated by intracellular Ca (Cai), K, Cl, Na and pH, whereas Ang
II and aldosterone modulate Ca1, K, Cl, Na and pH in their
mechanism of action. Thus, RAAS is activated by and subse-
quently modulates Ca and chemiosmotic constituents (ions and
water driven by proton movement). The specific sites and
mechanisms of action of Ca and chemiosmotic forces (K, Cl,
pH and water movement) were considered in some detail in a
previous review, with only a brief consideration of the intra-
renal control of renin and prorenin secretion, renin profile, and
mechanisms of subcellular dysregulation in several specific
cases of renin disorder [4].
Most renin disorders present a biphasic plasma renin profile.
The pathogenesis of benign renovascular hypertension during
normal salt balance is most accurately described by an initial
elevation of plasma renin activity (PRA), aldosterone, plasma
volume, and retention of salt and water immediately after renal
artery constriction [1]. This initial phase is characterized by
secretory hyperresponsivity since an identical stimulus pro-
vokes an exaggerated response [5]. Later on PRA returns to
"normal" or below normal despite maintained stimulation. This
latter phase is termed renin hyporesponsive because the PRA is
much lower than expected for an identical level of stimulation
(Fig. IA). The pathogenesis of experimental congestive heart
failure also demonstrates a biphasic PRA profile [6]. Constric-
tion of the thoracic inferior vena cava initially leads to an
increase in renin and aldosterone secretion, sodium retention,
and plasma volume expansion. Later on during maintained
constriction PRA returns to normal or below. Again, the initial
phase was demonstrated to be renin hyperresponsive, whereas
the later phase was renin hyporesponsive (Fig. 1B). Diabetic
induction with streptozotocin is a final example of the biphasic
PRA profile often seen in the pathogenesis of renin disorders
[7]. One week after diabetic induction PRA increases almost
twofold (Fig. lC). However, by the third and fourth week PRA
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reached subnormal levels. Renin hyporesponsivity has been
observed in a number of other clinical and experimental renin
disorders [41.
Possible mechanisms of renin hyporesponsivity will be the
chief focus of this brief review. First, we will briefly describe
the phenomenon in diabetes mellitus and other clinical disor-
ders classified along the lines of renin hyporesponsivity [4].
Second, we will critically evaluate what is currently known
about intrarenal control of renin and prorenin secretion and the
role of physical equilibrium of the afferent arteriole in modulat-
ing secretion. The role of the macula densa in the processing of
prorenin to renin will be reviewed critically in view of a recent
line of direct evidence as well as recent proposals for a
physiological as well as pathophysiological role of prorenin
itself. Using allometric analysis it has been observed that
kidneys from animals of greater body weight secrete a greater
proportion of their total secretory package as prorenin. The
significance of this observation will be discussed with reference
to allometric analysis of other aspects of renal function. Third,
we will identify subcellular sites of potential dysregulation in
renin secretory hyporesponsivity, and therefore set the stage
for further analysis of the renin secretory pathway at the
biochemical and molecular levels in an attempt to find success-
ful therapeutic strategies.
Diabetes melhtus and low renin syndrome
Stages of renin hyporesponsiveness characterize a fair num-
ber of clinical disorders (Table 1). As shown in Figure 1, the
renin-hyporesponsive phase is usually associated with estab-
lished disease in hypertension, heart disease, and diabetes.
Long standing diabetes (17 years) was reported with over 70%
as "low-renin" [14]. Primary aldosteronism is a typical example
of the blunted renin responsiveness [8]. The hyporesponsivity
remains the same whether the cause of aldosterone excess is
aldosterone-producing adenoma, idiopathic hyperaldosteron-
ism, intermediate hyperaldosteronism, or glucocorticoid-reme-
diated hyperaldosteronism [4]. Thyroid deficiency is another
example [9]. The majority of acromegalic patients have a
generalized lower PRA compared to normals, and hypertensive
acromegalics have an even more profound hyporesponsivity to
conventional stimulation [10]. Pituitary deficiency is an estab-
lished case of renin secretory hyporesponsivity [11—13]. Addi-
tional cases include Blacks (particularly African Americans)
[161, late stages of experimental pheochromocytoma [17], and
chronic salt excess [18]. Including the recently described New's
syndrome of apparent mineralocorticoid excess and Gordon's
syndrome of hypertension with hyperkalemia despite normal
GFR, renin secretory hyporesponsivity has been identified in
over 23 disorders [4], including polycystic kidney disease and
most cases of end-stage renal disease. It is this whole matrix of
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Fig. 1A. Sequential changes in systemic (aortic) and renal arterial pressures and plasma renin activity (PRA) in experimental benign
hypertension. Used with permission from Dzau et al [175]. B. Responses in the conscious dog to thoracic inferior vena caval constriction and the
development of moderate congestive heart failure. Used with permission from Watkins et at [6]. C. Plasma levels of glucose and renin activity in
streptozotocin-diabetic rats as a function of duration. Used with permission from Kikkawa et al [7].
Table 1. Basal plasma renin activity (PRA), renin secretion and
secretory responsiveness in extreme cases of low renin syndrome
Case
Basal PRA or
renin secretion
Stimulated PRA
or renin
secretion Reference
Diabetes mellitus (type I) low (normal) blunted [141
Diabetes mellitus (type I) low (normal) blunted [151
Primary aldosteronism low blunted [8]
Thyroid deficiency low blunted [9]
Acromegaly low blunted [10]
Pituitary deficiency low blunted [11]
Black Americans low blunted [161
Pheochromocytoma low blunted [17]
Chronic salt excess low blunted [18]
Diabetes mellitus, acromegaly, and pheochromocytoma may also
have high or "normal" basal PRA or renin secretion, but in established
phases of these diseases the predominant feature is low renin.
clinical (and experimental) disorders characterized specifically
by renin secretory hyporesponsivity that has been termed low
renin syndrome (LRS) [4],
There are many reasons why these seemingly "different"
clinical and experimental disorders should not be clustered
under a single syndrome, except one. LRS would constitute an
immediate source of readily available information pointing to
similarities, rather than differences. In several cases of LRS
such as experimental diabetes mellitus [19], mineralocorticoid
excess [20], pituitary deficiency [13, 21], Blacks in general [22],
and renal insufficiency [23], detailed information is already
available, even at the molecular level. In all cases examined
there is one striking similarity: renin secretory hyporesponsiv-
ity [4]. In the context of this similarity and a brief consideration
of what is currently understood about the renin secretory
pathways at the subcellular level, it has been suggested that
from signal recognition, transduction, and transformation to
production from rough endoplasmic reticulum (ER) to Golgi
stacks and finally to secretion-ready mature secretory granules
releasing their contents to the extracellular space there are at
least 23 separate molecules that are potential targets of attack in
any of the disorders clustered under LRS [24]. To unify the
seemingly disparate renin (and prorenin) profiles demonstrated
in LRS, one recent review approached the problem from the
point of view of synthesis, processing and export at the intra-
cellular level while backing into problems encountered during
renin abnormal expression [4]. The role of Ca and chemios-
motic forces was considered in some detail [4]. That approach
led the way to the discovery of LRS as a pervasive clinical
disorder characterized chiefly as a disease of defects in intra-
cellular processing, trafficking, and exporting [4]. In addition,
the approach pointed to more than few significant intracellular
regulatory sites which may be prime targets for pathological
attack, and therefore therapeutic focus [4]. In opposition to the
earlier approach, however, here we shall attempt to see in what
ways a fair number of the seemingly different disorders which
constitute LRS may lead to a similar picture, and thereby
provide the most cogent scientific justification for classifying
them as LRS. Although much is now known in terms of plasma
renin abnormal expression in LRS cases such as rheumatoid
vasculitis [25], Parkinson's disease, amyloidosis and progres-
sive autonomic failure [26], it is from diabetes mellitus that a
great deal of relevant information has arisen [19], particularly
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low-renin diabetic hypertension [221 where the pathophysiology
is well described.
Several pathologies have been documented to be associated
with LRS. In the late stages of renovascular hypertension
(phase III, characterized by renin hyporesponsivity [1]) we
often see atherosclerosis, arterial fibrodysplasia, renal artery
thrombosis (or aneurysms), polyarteritis nordosa, neurofibro-
matosis, along with a variety of abnormal electrolyte imbal-
ances [27]. In low-renin essential hypertension nephrosclerosis
is sometimes a predominant renal feature. It has been postu-
lated that the vascular changes of nephrosclerosis cause a
reduction in the compliance of the afferent arteriole and that
this underlies the mechanism of renin hyporesponsivity [28].
This hypothesis will be considered below in the general context
of the site(s) of impairment. In New's syndrome of apparent
mineralocorticoid excess (particularly in adolescents) we see a
profound hypokalemia, suppressed ACTH and all known cor-
ticosteroids, and refractoriness to spironolactone treatment
[29]. The clinical features of Gordon's syndrome is often muscle
weakness, shortness of stature, intellectual impairment, and
excess dental abnormalities [30]. In hyporeninemic hypoaldo-
steronism we see nonoliguric renal disease, hyperkalemia and
hyperchloremic acidosis as the chief features defining LRS [31].
In acromegaly the profile often resembles that reported in
low-renin essential hypertension and primary aldosteronism
[32]. In diabetes mellitus diffuse glomerular lesions and the
so-called Kimmelstiel and Wilson lesions of the microvascula-
ture have been reported [3]. The former are most frequently
associated with diabetic nephropathy (a classic case of LRS)
with the associated proteinuria and eventual renal failure [3].
Christlieb [3] pointed out that arteriosclerotic changes are seen
in LRS cases beside diabetics, but what is striking in diabetes is
that the arteriolar hyalinization attacks both the afferent and
efferent arterioles, and in extreme cases it closes the lumen of
the afferent. These changes have been found to have profound
effect on RS [33]. Perhaps equally significant is the observation
of a strong correlation between the severity of the glomerular
nodular lesion and renin responsivity factors [3]. At the mac-
roscopic level renin hyporesponsivity in diabetes is often asso-
ciated with nephropathy, neuropathy, and ketoacidosis [34].
Intrarenal control of renin and prorenin secretion
The JG cell occupies a unique position among secretory cells
in terms of the variety and complexity of its control mecha-
nisms. Its position in the wall of the afferent arteriole allows it
to respond to some biophysical manifestations of blood pres-
sure as well as to biochemical effects of hormones and neuro-
hormones in plasma. Additionally, the JG cell is subject to
sympathetic control and is also influenced by aspects of tubular
function by way of the macula densa. All these diverse signals
impinge on the JG cell, which must somehow integrate them to
provide the appropriate measure of RS and, therefore, RAAS
activation. An attempt to describe briefly these routes and
control mechanisms is given below. The next two sections
attempt to describe how the integration of the various control
mechanisms might be achieved. Central to the consideration of
integration are three features: two related to the environment of
the JG cell and one to its secretory activity. First, any myogenic
activity of the afferent arteriole in support of renal blood flow
autoregulation will influence the "hemodynamic environment"
of the JG cell and its secretory function. Secondly, the require-
ment for the afferent arteriole to be in physical equilibrium
provides a mechanism for defining the hemodynamic environ-
ment of the JG cell and its secretion of renin. Thirdly, the
differential release of renin and prorenin from the kidney is a
macula densa-mediated phenomenon which ensures a particular
degree of activation of RASS by the afferent arm (afferent
arteriole) is matched to the characteristics of the efferent arm
(the nephron). The implication of the latter point is that the
importance of circulating renal prorenin resides not in its
potential to contribute to the expression of RAAS via activa-
tion, but in its very inactivity.
Intrarenal control of renin secretion
Classically, the renin secretory activity of JG cells is con-
trolled by a number of discrete sensors which differ in stimulus
modalities and pathways for signal transduction. These routes
have been described as baroreceptor, neurogenic, hormonal,
and macula densa regulation [35—38].
Baroreceptor control. There is ample evidence of an inhibi-
tory effect of renal perfusion pressure on RS mediated at the
level of the afferent arteriole [39, 40]. The original concept of a
baroreceptor responding to pressure [41] has been expanded to
include the afferent arteriolar radius and tissue pressure contri-
butions to transmural wall tension [35] and its more detailed
variant, stretch [42]. More recent studies [43] suggest that
changes in shear stress related to changes in pressure-induced
flow might also contribute to the renin response to pressure.
Although the proper functioning of the baroreceptor in situ
requires the afferent arteriole to be intact, direct evidence
suggests that mechanical deformation can alter renin release at
the level of the individual JG cell [44]. Calcium plays a vital role
in coupling mechanical stimulation of the JG cell to inhibition of
RS. Increased stretch increases Ca influx into JG cells which
inhibits RS, with the increased Ca-conductance mediated by
stretch-activated channels (SACs) [42, 44]. The Ca-dependence
of baroreceptor function is demonstrated by the observations
that Ca-channel blockers prevent the inhibitory effect of high
pressure on RS, and the inhibitory effect of high pressure on RS
depends on extracellular Ca [38]. Recently, it has been sug-
gested that Ca1 exerts its inhibitory effect on RS via activation
of KCI and water efflux from the cell mediated by a Ca-
activated chloride channel in the surface membrane [45]; and
via deactivation of KC1 and water influx into secretory granules
mediated by a KC1-H exchange transporter in the granular
membrane [4]. Although the mechanism for signal transduction
at the JG cell membrane remains to be fully defined, blood
pressure effectively remains the "physiological variable" to
which the baroreceptor responds [46].
Neurogenic control. Since the description of the innervation
of the JG apparatus [47], an impressive amount of evidence has
accumulated suggesting that RS is stimulated by a /3-adrenergic
mechanism [48]. /3-Adrenergic receptors are coupled to adeny-
late cyclase in many tissues [49] and a cAMP-mediated effect
for RS is therefore implicated. Compounds such as glucagon
and forskolin, which are known to increase cAMP, stimulate
RS [50, 51]. Although /3-adrenergic agonists can stimulate RS in
the absence of a fully functional baroreceptor mechanism [52],
in situ it is likely that hemodynamic effects of sympathetic
activity can interact to modify RS. Thus, RS is affected by low
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frequency renal nerve stimulation, sodium excretion by me-
dium, and vascular resistance by high frequency [53].
Hormonal control. A variety of locally-produced and circu-
lating compounds can affect RS. These include angiotensin,
vasopressin, ANP, parathyroid hormone, glucagon, endothelin,
prostaglandins, histamine, and dopamine [37, 481. Perhaps the
most important of these in terms of the feedback control of
RAAS is angiotensin H. The inhibitory effect of angiotensin H
on RS requires extracellular Ca [54] and is attenuated by
Ca-entry blockade [55], suggesting the inhibitory effect is me-
diated by calcium influx [55].
Macula densa control. The close apposition of the macula
densa with the renin-secreting JG cells provides the anatomic
basis for the direct control of RS by nephron function. The
original hypothesis of Vander [56] proposed an inverse relation-
ship between RS from JG cells and sodium load at the macula
densa. The demonstration of an inverse relationship between
sodium chloride delivery to the macula densa and RS in
microdissected, perfused JG apparatus [57] has provided con-
vincing support for the original hypothesis. Ion substitution
experiments in rats, however, indicate the importance of chlo-
ride rather than sodium in mediating the macula densa control
of RS [58, 59]. These observations have been strengthened by
experiments in which the substitution of chloride with glu-
conate suppress RS from superfused rat glomeruli [43]. More-
over, the suppression of RS by chloride substitution was
reversed by removal of Ca from the superfusate, further dem-
onstrating the central role played by Ca in the control of RS,
even when the effector is via a macula densa pathway.
Role of physical equilibrium of the afferent arteriole in
determining renin secretion
The afferent arteriole is intimately involved in two important
renal phenomena. It is the primary site for the vascular resis-
tance changes that mediate RBF autoregulation and it contains
the modified smooth muscle cells, the JG cells, that release
renin. The interdigitation of the smooth muscle responsible for
blood flow autoregulation and the JG cells responsible for RS
suggests a close functional relationship. Thus, it has been
suggested that RS mediates autoregulation [60—62] and also that
autoregulatory responses determine RS [63, 641. More specifi-
cally, since there is ample evidence that the afferent arteriole
acts as an autonomous baro- or stretch receptor controlling RS
[39, 40], and because the afferent arteriole demonstrates a
myogenic response to pressure [65, 661, it is necessary that any
realistic consideration of RS from JG cells in situ must take into
account the concurrent myogenic activity of the smooth muscle
cells (this is of particular importance for the kidney as its
vascular response to changes in perfusion pressure are large,
leading to near-constant RBF over a wide range of blood
pressures). Although opinion is divided, a fair amount of
evidence suggests that afferent arteriolar smooth muscle is
unresponsive to angiotensin [65, 671 and that the primary
intrarenal site for its vasoconstrictor activity is the efferent
arteriole [68]. Therefore, the direct contribution of RS to
afferent arteriolar contractile activity is likely to be small.
Rather, it is the myogenic activity of the afferent arteriole which
will set the hemodynamic environment of the arteriole and
which may. in consequence, determine RS [64]. Similarly,
humoral agents and neurotransmitters may well affect the JG
cell directly, but in situ any concurrent action on vascular
smooth muscle activity is likely further to influence RS by
altering the hemodynamic environment of the afferent arteriole
[53].
The myogenic response of the vasculature to increased
pressure was first proposed almost a hundred years ago by
Bayliss [69], but only recently has enough evidence provided to
define the subtle and elusive mechanism. Central to any de-
scription of the myogenic response is the control loop initiating
and maintaining contractile activity within the arteriolar wall.
Although it has been suggested that myogenic activity adjusts
itself to keep wall tension constant [70], such a control mech-
anism may be unnecessarily complicated since the most basic
"feedback loop" operating within a blood vessel is the vessel's
maintenance of physical equilibrium and its response to physi-
cal dysequilibrium. The implications for blood vessels of their
requirement for physical equilibrium was first explored by
Burton [71] and later incorporated into mathematical descrip-
tions of the myogenic response and RBF autoregulation [70, 72,
73]. Most recently, a mathematical model for RBF autoregula-
tion based on equilibrium theory [74] has been extended to
include the prediction of RS [63]. The salient features of the
model are illustrated in Figure 2 and are summarized as follows:
(1) Blood flow through the afferent arteriole is determined by
the perfusion pressure and the arteriolar radius.
(2) The arteriolar radius is determined by the balance of two
opposing forces: a distending force and a constricting force.
Under stable conditions, the radius of the blood vessel will
be such that these forces are equal and opposite (that is, the
vessel is in physical equilibrium). Changing these conditions
(such as changing blood pressure) will change the forces and
bring the vessel into physical dysequilibrium; the radius will
change accordingly to reestablish equilibrium (that is, if the
change in blood pressure is such that distending force >
constricting force, then dilation will occur; if distending
force < constricting force, then constriction will occur).
(3) The distending force is related to the LaPlace equation, and
is dependent on internal and external arteriolar radii, blood
pressure, and tissue pressure.
(4) The constricting force is made up of two components: a
passive tension related to the elastic properties of the vessel
and the vessel radius, and an active tension which com-
prises the myogenic response of vascular smooth muscle to
stretch [421. Stretch (which is determined by hemodynamic
factors such as blood pressure and vessel radius) activates
SACs in cell membranes to increase Ca influx and so
increase tension development.
(5) JG cells, being modified smooth muscle cells, also respond
to stretch with a modified Ca influx. RS is then inversely
related to Ca [4].
Figure 3A is an equilibrium diagram illustrating the way in
which the requirement for physical equilibrium determines
arteriolar radius for a given set of hemodynamic conditions [71].
The dashed line shows how the calculated distending force
varies with arteriolar radius at a given blood pressure (100 mm
Hg). The solid line shows how the calculated constricting force
(active plus passive tensions) varies with arteriolar radius at the
same pressure. The radius at which the lines intersect is stable
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Wall of
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arteriole
Radius Extracellular calcium
Calcium ettlux rate
Ca via other routes
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Fig. 2. Features of the afferent arteriole in its regulation of renal blood flow and renin secretion. Key features are that: (1) blood flow through the
afferent arteriole is determined by the perfusion pressure and the arteriolar radius. (2) The arteriolar radius is determined by the balance of two
opposing forces—a distending force and a constricting force. Under stable conditions, the radius of the blood vessel will be such that these forces
are equal and opposite (that is, the vessel is in physical equilibrium). Changing these conditions (that is, changing blood pressure) will change the
forces and bring the vessel into physical dysequilibrium; the radius will change accordingly to reestablish equilibrium (if the change in blood
pressure is such that distending force > constricting force, then dilation will occur; if distending force < constricting force, then constriction will
occur). (3) The distending force is related to the LaPlace equation, and is dependent on internal and external arteriolar radii, blood pressure, and
tissue pressure. (4) The constricting force is made up of two components: a passive tension related to the elastic properties of the vessel and the
vessel radius, and an active tension which comprises the myogenic response of vascular smooth muscle to stretch. Stretch (which is determined
by hemodynamic factors such as blood pressure and vessel radius) activates SACs in cell membranes to increase Ca influx and so increase tension
development. (5) JG cells, being modified smooth muscle cells, also respond to stretch with a modified Ca influx. Renin secretion is then inversely
related to Cai. Adapted from [74].
since distending force equals constricting force. Radii to the left
and right of that point are unstable as dysequiibrium prevai's.
To the left, distending force is greater than constricting force so
the vessel dilates and the radius moves towards the stable
radius. To the right, constricting force is greater than distending
force so the vessel constricts and the radius moves towards the
stable radius. Note that as the radius moves, the magnitudes of
the tensions vary (for example, although movement towards the
stable radius from a larger radius involves a reduction in the
myogenic response, the constricting force is still greater than
the distending force so the radius continues to decrease) illus-
trating the iterative, feedback nature of operation. Thus, a
change in radius changes the myogenic response which changes
the radius, which changes the response, etc. [63, 74].
In practice, however, it is not a change in radius that initiates
dysequilibrium. It is a change in some other factor which alters
the distending/constricting forces and so causes the radius to
shift to a new stable value. For example, a change in blood
pressure produces an autoregulatory adjustment in renal resis-
tance (that is, afferent arteriolar radius). This is illustrated in
Figure 3B, which shows the distending and constricting curves
for two different pressures. The stable radius at each pressure
occurs at the intersection of the corresponding distending and
constricting curves. At 100 mm Hg, the stable radius is 9.78 s.
When the pressure is raised to 140 mm Hg, the altered depen-
dencies of distending and constricting forces on radius is such
that the stable radius is now 9.10 /.L. On increasing the pressure
from 100 to 140 mm Hg, according to the requirement for
equilibrium illustrated in Figure 3B, the vessel must adjust its
radius to this new value. A rise in blood pressure is therefore
met with a reduction in radius, a rise in resistance, and blood
flow autoregulation [63, 74].
The "search" for a new stable radius that characterizes the
response to dysequiibrium involves a dynamic interplay be-
tween changing radius and changing distending, passive, and
active (myogenic) tensions. Once the new radius is reached,
however, the smooth muscle cells will demonstrate a level of
active tension development determined by their Ca1, which in
turn will be determined by the degree of "stretch". Similarly,
the JG cells (being modified smooth muscle cells sharing a
similar afferent arteriolar environment) will also demonstrate a
similar intracellular Ca. Since RS is Ca-dependent and is
inversely related to intracellular Ca [4], RS can be calculated for
any set of hemodynamic parameters once the afferent arteriole
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Fig. 3. Equilibrium diagrams showing the effects of some consequences of dysequilibrium. A. The way in which the requirement for physical
equilibrium determines arteriolar radius for a given set of hemodynamic conditions. The dashed line shows how the calculated distending force
varies with arteriolar radius at a given blood pressure (100 mm Hg). The solid line shows how the calculated constricting force (active plus passive
tensions) varies with arteriolar radius at the same pressure. The radius at which the lines intersect is stable since distending force equals
constricting force. Radii to the left and right of that point are unstable as disequilibrium prevails. To the left, distending force is greater than
constricting force so the vessel dilates and the radius moves towards the stable radius. To the right, constricting force is greater than distending
force so the vessel constricts and the radius moves towards the stable radius. Note that as the radius moves, the magnitudes of the tensions vary
(such as, although movement towards the stable radius from a larger radius involves a reduction in the myogenic response, the contricting force
is still greater than the distending force so the radius continues to decrease) illustrating the iterative, feedback nature of operation. Thus, a change
in radius changes the myogenic response which changes the radius, which changes the response, etc. B. The distending and constricting curves
for two different pressures. The stable radius at each pressure occurs at the intersection of the corresponding distending and constricting curves.
At 100mm Hg, the stable radius is 9,78 s. When the pressure is raised to 140 mm Hg, the altered dependencies of distending and constricting forces
on radius is such that the stable radius is now 9.10 . On increasing the pressure from 100 to 140 mm Hg, according to the requirement for
equilibrium, the vessel must adjust its radius to this new value. A rise in blood pressure is therefore met with a reduction in radius, a rise in
resistance, and blood flow autoregulation. Adapted from [74].
achieves equilibrium. It should be noted that, within the above
model, Ca1 and therefore RS is a consequence of the way the
afferent arteriole responds to its requirement for equilibrium. In
other words, the myogenic response to hemodynamic variables
such as pressure sets the conditions for RS.
The above model fairly successfully predicts RBF and RS
under a variety of experimental conditions [63, 74]. These are
summarized below:
(1) Increased RS in the sub-autoregulatory range and its sup-
pression over the autoregulatory range of renal perfusion
pressures.
(2) Increased RBF and RS with increased tissue pressure.
(3) Changes in the pressure dependence of RBF and RS with
changes in extracellular Ca.
(4) Increased RS and RBF with increased Ca effiux.
(5) Effects of vasoconstrictors on RBF and RS depends on Ca
and equilibrium status.
Generally, both experimentally and within the model, maneu-
vers which tend to produce vasodilation and increase flow tend
to increase RS. However, some studies have indicated that this
direct relationship between vascular resistance/flow and RS can
be reversed [51, 75]. Given, within the above model, the similar
determination of JG cell and smooth muscle Ca1, the exposure
of both cell types to similar hemodynamic environments, and
the common dependence on Ca, for RS and active tension
generation, any uncoupling of flow from RS within the model
would be a surprising and important prediction.
Figure 4 shows one qualitative comparison of model predic-
tions with experimentally derived data from isolated perfused
rat kidney. Using the perfused kidney, a recent report demon-
strated that forskolin (an activator of adenyl cyclase) increased
RS with a small increase in flow, and that simultaneous high
K-depolarization reversed the renin secretory and flow effects
of forskolin [51]. On the other hand, although the enhancement
of RS by forskolin was reversed by increased perfusion pres-
sure, flow was further increased rather than decreased by this
maneuver. On its own, high K-depolarization suppressed both
RS and flow. Evidence suggests that cAMP stimulates RS by
increasing Ca effiux [38], so the effect of forskolin was simu-
lated in the model by an increase in the Ca eftiux rate coefficient
of JG and smooth muscle cells (Fig. 2). High extracellular K can
increase Ca-influx by depolarizing cell membranes [38], so this
maneuver was simulated by increasing the activation of mem-
brane Ca channels (Fig. 2). Although differing in the absolute
magnitude of the percent changes from control values, the
directions in which theoretical flow and RS move in response to
the various simulations of experimental maneuvers are consis-
tent with the actual data (Fig. 4). In particular, high K blunts the
forskolin-induced increases in both RS and flow, but the inhib-
itory effect of high pressure on forskolin-induced RS is accom-
panied by the experimentally observed enhancement of flow.
These divergent effects of high K and increased pressure on
forskolin-induced changes in RS and flow may be explained
within the context of the model. The effect of increased
pressure is mediated by stretch-induced changes in Ca influx;
however, stretch is determined by factors other than perfusion
pressure, most notably arteriolar radius. On the other hand, the
depolarizing effect of high K on the cell membrane is direct and
effectively independent of hemodynamic parameters such as
pressure and radius. Thus, the increase in Ca1 caused by high K
will increase the constricting force within the model, but this
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force will not be opposed by an increase in distending tension
(as there is no increase in perfusion pressure) so the arteriolar
radius will stabilize at a lower value and both RS and flow will
be reduced. In contrast, the high pressure will increase both Ca,
and, therefore, the constricting force as well as the distending
force with the result that the arteriolar radius will stabilize at a
slightly higher value, decreasing RS but increasing flow.
The close qualitative match between experimental data and
theoretical prediction lends support to the proposition that the
model may reflect, albeit simply, the mechanisms determining
flow and RS in situ. Of particular importance within the model
are the central roles for physical equilibrium, myogenic auto-
regulatory behavior, and Ca in determining both flow and RS
from the kidney. It would appear that these latter two phenom-
ena cannot be considered independently in situ and that the
secretory activity of the JG cells is set to a large extent by the
myogenic determination of the hemodynamic environment to
which the JG cells are exposed and to which they respond.
The model does not account for two major aspects of RS:
firstly, the secretion of prorenin by the kidney, and secondly,
the macula densa control of RS. There is strong evidence that
these two phenomena are related [76—78]. The next section,
therefore, attempts qualitatively to relate the macula densa
control of proRS to the model described above.
Intrarenal control of prorenin secretion
Although it is well established that inactive (in terms of ability
to generate angiotensin I from angiotensinogen in plasma) forms
of renin are released by the kidneys of a number of species
under a variety of conditions, and that the identity of circulating
inactive renin is most likely prorenin, much less is known about
the control of inactive compared to active RS. The main
reasons for this discrepancy are methodical differences/difficul-
ties, extrarenal sources of prorenin, and species differences.
Fig. 4. Comparison between renin secretion
(RS) and renal blood flow (Flow) data as
derived from experimental [51] and theoretical
[74] studies. All values represent % change
from control. Left panels were derived from
published experimental studies (A and C)
whereas the right panels were derived from
model calculations (B and D). All
+ experimental studies were conducted in the
isolated perfused kidney of the rat [52].
Methodological differences/difficulties. The most widely used
methods for assaying pro-forms of renin rely on measuring the
ability of samples to generate angiotensin following activation
of the inactive enzyme. Prorenin is then the difference between
activated (total renin) and non-activated (active renin) samples.
Methods for activation include acid dialysis [79], cryoactivation
[80], and trypsin hydrolysis [81]. Although these methods are
often designed to maximize renin activation within a particular
laboratory and for a particular species, it can only be assumed
that all the prorenin present is activated and renin destruction is
minimized. Methodological differences in activation protocols
also hamper comparison between species and laboratories.
However, such indirect measurements of renin do have the
particular advantage of estimating the contribution and poten-
tial contribution of the different renin molecules to the in vivo
expression of RAAS. More recently, direct radiometric assays
for renin and prorenin have been developed utilizing antibodies
directed against the active site [82, 83] for active renin and
against the pro-segment [84, 85] for prorenin. While these offer
a quicker, simpler, and more direct estimate of (pro)renin (renin
+ prorenin), the measurements are of renin mass, not of
biological activity. Neither direct nor indirect methods provide
the complete answer, and it would seem that Slater and Haber's
1979 assessment of our view of prorenin as being "through a
glass darkly" is still fairly appropriate [86].
Extrarenal sources of prorenin. Study of renal proRS in
various species is complicated by possible interference from
extrarenal sources of prorenin. Prorenin is demonstrable in the
plasma of anephric man, but not in anephric sheep (D. Lush,
unpublished observations), dogs [87] or rabbits. There have
been conflicting reports regarding the presence of plasma
prorenin following nephrectomy in rats, possibly due to meth-
odological differences [88], although the submandibular gland
has been implicated [89]. Prorenin is also associated with the
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reproductive organs [90, 911. Neither systemic nor local roles
for extrarenal prorenin have been established, although it has
been noted that prorenin tends to be associated with organs
with high blood flow rates, which prompted the proposition that
prorenin causes renal vasodilation [92]. Even if a role for
extrarenal prorenin is found, the question still remains as to the
relevance of extrarenal renm to the renally-mediated expression
of RAAS. In vitro preparations provide the opportunity of
studying renal prorenin secretion in isolation, yet few studies
have been published compared to those in whole animals.
Attempts at determining renal prorenin secretion in intact
animals by measuring arteriovenous differences can be con-
founded by large coefficients of variation and the possibility of
the renal clearance of prorenin as well as secretion [93].
Species djJferences. In most investigations of prorenin the
measured variable is plasma prorenin. Given the variable
contribution of extrarenal sources to circulating prorenin, as
well as technical difficulties regarding plasma prorenin estima-
tion [94], it is hardly surprising that no consistent picture
emerges regarding possible variation in plasma prorenin be-
tween the commonly studied mammalian species (mouse, rat,
rabbit, cat, dog, hog, sheep, human). However, in order to
examine inter-species variation in the differential secretion of
renin and prorenin by the kidney, in vitro preparations such as
perfused kidneys and kidney slices offer two distinct advan-
tages. First, renin and prorenin measured is of renal origin only.
Secondly, the interfering effects of plasma are eliminated. Thus,
in vitro preparations offer a potential means of studying species
differences.
The most easily quantifiable difference between species is
body size, and allometric analysis can be used as a comparative
description of the effect of body size on biological parameters.
This form of analysis can demonstrate functional trends and
constraints not otherwise apparent from consideration of single
species [95]. The relationship between the estimated percent of
total renin released in the inactive, pro-form and body weight is
ifiustrated in Figure 5 for eleven in vitro studies covering five
species [76—78, 96 103]. The relationship is significant (P <
0.02), such that kidneys from animals of greater body weight
tend to secrete a greater proportion of their renin in the
pro-form. The possible significance of this observation will be
discussed below with reference to the allometry of other
aspects of renal function.
Allometric analysis of renal/cardiovascular function and its
implication for (pro)renin secretion
Although methodological differences, extrarenal sources, and
species differences are important, perhaps the major barrier to
a fuller understanding of secreted prorenin is conceptual.
Whereas the physiological role of active renin is to catalyze the
production of angiotensin I from angiotensinogen and thereby
determine the expression of RAAS, it has been difficult to
ascribe a demonstrable role to prorenin within this hormonal
system [93, 1041, outside of its precursor function. The most
obvious role for prorenin would be a contribution to the normal
expression of RAAS through post-secretory activation—a role
that follows naturally from the renin activating and angiotensin
generating steps of the prorenin assays. From a variety of
attempts to demonstrate post-secretory activation [105—1081,
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Fig. 5. Direct relationship between the percent of total renin released
in the inactive (prorenin) form and body weight as developed by
allometric analysis. Data were derived from eleven in vitro studies in
the five species shown in the top panel. The relationship is significant (P
<0.02), such that kidneys from animals of greater body weight secrete
a larger proportion of their total renin secretory package in the
pro-form.
the general consensus is that post-secretory activation of pro-
renin does not make a major contribution to the normal func-
tioning of RAAS [93, 104]. Indeed, the most recent physiolog-
ical role attributed to prorenin is that of a vasodilator [92]. In a
radical and imaginative paper, it was speculated that prorenin
binds to receptors in certain vascular beds where it undergoes a
conformational change leading to activation and production of
local angiotensin [92]. Yet in the vast majority of renin disor-
ders, including diabetes mellitus with many of its complications
characterized by excess prorenin [26], neither excess angioten-
sin II, its metabolites, nor abnormal renal vasodilation has been
observed. What then must be the role of prorenin? There is one
consistent assumption within the whole spectrum of views
concerning the physiological role of circulating prorenin, even
those that suggest a vasodilator role [92], which is that the
contribution prorenin makes to the overall expression of RAAS
is post-secretory and arises from an increase in its catalytic
activity. Given the lack of clear evidence for this, and assuming
that circulating prorenin of renal origin does fulfill a significant
physiological role (in being the only precursor of renin) rather
than represent a by-product of a default renin secretory path-
way, the possibility remains highly likely that its physiological
significance resides in its very lack of catalytic activity. The
suggestion that differential secretion of renin and prorenin
represents a true locus for controlling the expression of RAAS
has been argued strongly by Noble [109].
Clues as to why the JG cell should adopt the curious tactic of
determining the expression of RAAS (via angiotensin produc-
tion) by controlling the overall activity as well as the amount of
the renin it secretes may come from a consideration of the
differing roles of the afferent arteriole and macula densa in the
overall functioning of RAAS at the single nephron level. Re-
cently, the implications for the whole organism of examining
the functioning of RAAS from the perspective of the single
nephron have been explored [110]. The major link between the
whole organism and renal/nephron function is body size. Body
size determines the basal metabolic rate, and renal function
supports this metabolism.
It is possible, therefore, that the variation in prorenin secre-
tion with body size demonstrated in Figure 5 is linked to other
0
0
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size-related aspects of nephron function. The basis for such a
link is considered below using data from the comprehensive
analysis of the scaling of renal function in mammals by Calder
and Braun [95]. The usual form of the allometric equation is:
Y = aMb
where Y is the variable under study, M is body mass, and a and
b are constants. Of particular interest is the exponent, b, which
has a value close to 0.75 for mammalian basal metabolic rate.
As expected, the gross renal support of mammalian metabolism
scales to body size with similar values for b. Thus, RBF, GFR
and urine production rate scale as M°77, M°72, and M°75,
respectively. However, in terms of kidney structure, this equiv-
alence does not hold. In particular, the number of glomeruli
scales as M°62. Since the rate of increase in the number of
glomeruli is less than the rate of increase in GFR, each
glomerulus must handle a larger fraction of the GFR as body
size increases. For example, from the data presented by Calder
and Braun [95], the SNGFR of a 100 kg animal is twice that of
a 0.1 kg animal, with the increase in SNGFR presumably
accounted for by the increase in glomerular surface area.
Similarly, as body size increases, each nephron must contribute
more to the urine produced (that is, it must effectively reabsorb
less).
Nephron function, through sodium/water reabsorption, rep-
resents the long-term efferent arm of RAAS. Thus, as body size
increases and the contribution of each nephron to the normal
excreted load also increases, it may be argued that a smaller
induction of RAAS would be necessary to achieve normal
salt/water balance. This implies that the JG cell needs to receive
information concerning the size-related excretory load of the
nephron. The macula densa mechanism may serve this func-
tion. Thus, a larger nephron from a larger animal may reduce
activation of RAAS through the macula densa mechanism. In
terms of a mechanism, NaC1 concentration at the macula densa
is regarded as a simple function of loop of Henle flow rate [111]
and, presumably, SNGFR. In addition, there is an inverse
relationship between macula densa Cl transport and RS [112].
In each of the nephrons of larger mammals, therefore, it is
suggested that the higher SNGFR and tubular flow may in-
crease Cl transport at the macula densa and inhibit RS. Thus,
RAAS would be modulated downward, and the nephron would
achieve its aim of a greater contribution to urinary excretion.
Figure 5 suggests that this downward modulation of RAAS in
larger animals is achieved by increasing the relative percentage
of renin released in the pro-form rather than by decreasing the
total amount of renin released.
Although the macula densa control of prorenin may occur
through the intracellular pathway considered previously [4], the
variation in the relative amounts with body weight suggested by
Figure 5 may be viewed from an allometric perspective. Thus,
theoretical modeling of the renal afferent arteriole suggests that
the renin secretory response is exquisitely sensitive to distur-
bances of the physical equilibrium of the vessel and this, in
turn, is influenced primarily by the myogenic autoregulatory
response of the vascular smooth muscle. However, whereas the
efferent arm of RAAS is sensitive to body size (through
increases in SNGFR and single nephron urine flow with in-
creased body size), it is likely that the afferent arm represented
by the hemodynamic environment of the afferent arteriole is
not. Renin release is inversely related to stretch-induced Ca
influx, and stretch is influenced by blood pressure and afferent
arteriolar radius [63]. Blood pressure is effectively size-inde-
pendent [95] and measures of afferent arteriolar lumen diameter
are similar in rabbits [65], dogs [74, 113], and humans [114].
This implies that, as body size increases, there is an increasing
disparity between the magnitude of the renin-secretory activity
of the afferent arm (through size-independent hemodynamic
stimuli) and the ideal effect of this response on the efferent arm
(through size-dependent tubular function). Thus, in a larger
animal the same decrement in, say, blood pressure, may not
require the same magnitude of renin secretory/angiotensin-
mediated reabsorptive responses, since that animal's normal
renal function is achieved with larger nephrons which excrete
more of their filtered load. It is proposed that the macula densa,
by sensing this aspect of tubular function, modulates the basal,
baroreceptor-induced renin secretory response by varying the
proportion of renin released in the inactive, pro-form. Thus,
although the renin-secretory response of the baroreceptor is
essentially size-independent, the proportion of renin released in
the active form is varied by the macula densa to suit the
size-dependent characteristics of the nephron.
Apart from the direct relationship between body weight and
the percent of total renin released by the in vitro kidney in the
inactive form (Fig. 5), there are a number of experimental
observations which lend support to the proposal. First, differ-
ential release of (pro)renin is most often seen with maneuvers
which alter electrolyte balance and tubular function. Noble and
co-workers have shown that hemorrhage in the anesthetized
rabbit [115] and in conscious and anesthetized sheep [116],
calcium channel blockade in conscious sheep [117], and isopro-
terenol in anesthetized rabbits [78]—but not conscious sheep
[1 18]—increase both forms of renin in parallel. On the other
hand, dietary Na depletion in rabbits [119], and furosemide-
induced diuresis in anesthetized rabbits [120] and sheep [121] is
accompanied by a stimulation of renin and a reduction in
prorenin. Morgan and co-workers [122, 123] investigated the
influence of salt on the two forms at the level of the individual
JG apparatus in rats. Dietary Na depletion was associated with
an increase in the renin content of JG apparatuses with 30% of
the renin in a pro-form, and a disappearance of prorenin from
the circulation. Conversely, dietary Na loading was associated
with a fall in JG renin content; no prorenin could be demon-
strated in the JG apparatus, although 40% of plasma renin was
in the pro-form [122]. These results are consistent with in-
creased secretion of prorenin—with concomitant depletion of
JG stores—with sodium loading and, presumably, increased
delivery of NaCI to the macula densa. Indeed, increased
microperfusion of the late proximal tubule in rats is associated
with similar changes in JG renin and prorenin [123].
Secondly, there should be an increase in the proportion of
circulating prorenin during infancy and adolescence secondary
to increasing body size. Humans are born with a full comple-
ment of nephrons [124]. The rise in GFR which occurs during
infancy and adolescence [125] is achieved by an increase in
SNGFR secondary to increased glomerular capillary surface
area [126]. From the above proposal, the rise in SNGFR
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associated with maturation and increased body size may in-
crease NaCI delivery to the macula densa and increase the
relative proportion of renin released in the pro-form. The
overall activation of RAAS would be blunted, thereby allowing
each larger nephron to contribute more to overall urinary
excretion. Fractional Na reabsorption is, indeed, less in the
distal segments of older rats compared to younger rats, whereas
Na delivery to the early distal tubule is greater [127]. Thus, the
reduced distal Na reabsorption in older animals may be a
consequence of reduced activity of RAAS mediated by in-
creased NaC1 delivery at the macula densa.
In humans, a comparison of infants under one year with
children aged two to nine years suggested a reduced proportion
of plasma prorenin in the older children [128]. Another study
failed to demonstrate evidence for any change in the proportion
of plasma renin in the pro-form with age [129]. A third demon-
strated a greater proportion of total plasma renin concentra-
tion—but not activity (as measured by cryoactivation)—in the
pro-form in adults compared to children (66% vs. 50%), but no
statistical comparison was made [1301. A fourth study found
few significant changes between a number of age groups [131]
with a general trend towards increased proportions of prorenin
was apparent from one month to 16 years, but the data were not
subjected to regression analysis [131]. Nevertheless, two other
studies with a total of 161 subjects have indicated highly
significant negative correlations of plasma active renin with age
and highly significant positive correlations of plasma prorenin
with age, providing strong evidence that the proportion of
plasma renin in the inactive form rises with age and, therefore,
body size [132, 133].
Thirdly, the association with GFR provides additional sup-
port. Since it is proposed that the increased SNGFR normally
associated with larger nephrons from large animals increases
NaCI delivery at the macula densa and increases the proportion
of prorenin secreted, there should be a direct relationship
between prorenin secretion and (SN)GFR. It might be ex-
pected, therefore, that experimentally induced changes in GFR
may also affect prorenin secretion. One particular study docu-
ments the relationship between prorenin and GFR [87]. Over a
12 hour period following the release of 48-hour ureteral ligation
in dogs, GFR was positively and significantly correlated with
plasma prorenin. In the context of the above proposal, the
variation in prorenin is a consequence of the variation in
(SN)GFR. Ablation of renal tissue reduces the number of
nephrons available to support body metabolism. This produces
compensatory renal growth in which GFR may return to normal
[134]. From the above hypothesis, this could be associated with
an increase in the relative secretion of prorenin from the
remaining renal tissue, since compensatory growth is associ-
ated with an increase in nephron size, not number. Unfortu-
nately, there are no studies of the effect of compensatory renal
growth on the release of (pro)renin. SNGFR increases in both
renal ablation and streptozotocin-induced diabetes in rats,
apparently accompanied by increased NaCl transport at the
macula densa [135]. This form of experimental diabetes is
associated with reduced plasma active renin and increased
plasma prorenin [136], lending support for the profound control
of the macula densa on differential secretion of renin and
prorenin, especially in diabetes.
Subcellular renin profiling and potential sites of impairment
in diabetes mellitus and other cases of LRS
Although it is widely believed that the site of dysregulation in
renin hyporesponsive diabetes and other LRS cases is intra-
renal, only recently has enough evidence accumulated for
critical evaluation. This section presents a number of possibil-
ities and provides an assessment of the most promising for
further research, particularly in diabetes where a fair amount of
evidence is now available.
Several studies have attempted to identify the locus of renin
impairment in diabetes mellitus, particularly those cases with
low-renin diabetic hypertension [reviewed in 22]. Increased Na
retention (presumably at the macula densa) was suggested as an
explanation [137], but this remains controversial because sev-
eral workers have argued that it is Cl [1381 or perhaps osmolal-
ity [139] that triggers macula densa control of RS, not Na. As
discussed above, this proposal may be enriched by arguing in
terms of allometric analyses, but a detailed mechanism has not
been advanced for diabetes. Decreased afferent arteriolar dis-
tensibility has also been suggested as an explanation [1401 since
distensibility affects RS [141]. However, the magnitude of the
effect of decreased distensibility is small compared to other
factors [142] and may be insufficient to explain the powerful
suppression seen in diabetes. This is not to underestimate the
significant contribution of the hemodynamic environment of the
JG cell, but more to suggest that vascular distensibility can only
make a limited contribution as predicted from equilibrium
theory [63]. Furthermore, the renin hyporesponsiveness is also
observed in cases without reported alteration of afferent arte-
riolar distensibility [13]. Lack of insulin was also suggested as
an explanation for renal renin impairment [143, 144], and it was
suggests that insulin is necessary for the normal renin secretory
response [144]. This interpretation is at odds with studies
showing excessive (or normal) RS in diabetes in the absence of
insulin [140, 145, 146]. Furthermore, Cohen, Laurens and Fray
[147] have shown an inhibitory effect of insulin on RS, which
raises serious difficulties for the "insulin-dependent" theory
[143, 144]. Deceased sympathetic nervous system activity has
also been postulated as the site of impairment [3, 148], an effect
observed in isolated perfused kidneys [19]. In the majority of
studies, however, where renin secretory impairment has been
observed, the sympathetic nervous system was normal [137,
149, 150] or could be activated [3], suggesting that depressed
/3-adrenergic responsiveness may be one manifestation of the
pathogenesis of diabetes but upstream from a more fundamental
impairment. Finally, body fluid volume expansion was sug-
gested as the signal [3, 151]. Indeed, volume expansion has
been observed [3, 7, 150], but normal blood volume has also
been observed [137, 149]. Thus, the literature provides no
satisfactory signal which accounts for the majority of the data
on diabetes and low-renin diabetic hypertension at the extra-
renal level.
An intrarenal locus for renin secretory impairment has been
postulated. Christlieb [3] was the first to suggest that the defect
was in renin production and storage (or content). He supported
the proposition by showing a decreased renal renin content in
alloxan diabetes [3, 150], and others have confirmed these
findings in streptozotocin-induced diabetes [143]. However,
these results may have to be reinterpreted because the renin
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profile in streptozotocin-induced diabetes is biphasic: increas-
ing during the first week of streptozotocin and decreasing by the
fourth week (Fig. 1C). More recent studies have shown a
decisive increase in renal renin content with streptozotocin
[152]. Cohen, McCarthy and Rossetti [19] have shown a striking
increase in renal renin content in rodents (BB/W) with sponta-
neous diabetes. Chronic stimulation caused a further twofold
increase in renal renin content without significantly altering the
secretory hyporesponsiveness in these rats [19]. As will be
shown below, decreased renal renin content may not be a
general phenomenon in renin disorders such as diabetes. Fur-
thermore, the observation that diabetic rats with excess renin
were still hyporesponsive to secretagogue [19], suggests that
the impairment may be at a step distal to storage. Kidneys of
spontaneously diabetic rats released half as much renin though
they stored twice as much compared to non-diabetics [191. The
currently available evidence, therefore, suggests that the site of
the impairment must be somewhere along the secretory cas-
cade.
Subcellular fractionation, purification, and characterization
of the major components of the renin secretory pathways have
revealed significant clues as to the sites of impairment. Rough
ER and Golgi transport vesicles, mature secretory granules,
and plasma membrane subfractions with light microsomes have
been identified as important components of the renin secretory
cascade [4]. Subfractionation and purification studies have
allowed further assessment of these components in the context
of renin storage in a few animal models and in human diabetic
hypertension in an attempt to gain further insights into the
mechanisms of renin hyporesponsivity in LRS, especially as it
relates to storage and processing.
It has been suggested that the processing of prorenin to renin
is less efficient in diabetes and that this inefficiency may
contribute to the impairment in patients with diabetes, hyper-
tension or other renin hyporesponsivity syndromes [1531, and
an outline of possible hypotheses for the impairment has been
suggested [154]. The abnormality may occur during (or shortly
after) translation since several signals have been suggested to
act through identifiable promoter elements upstream on the 12.5
Kb renin gene [155, 1561. This hypothesis predicts a decreased
storage, an observation reported for only a small number of
LRS cases [4]. Impairment shortly after translation might be
expected to be revealed in the signal sequence and prosegment
of the precursor molecule. This suggestion may be challenged
by the observation that processing of the preprorenin molecule
is independent of the signal sequence and further processing of
the prorenin molecule is unaffected by the prosegment [156].
Furthermore, it was suggested that after the cleavage of the
signal sequence in the ER and upon N-glycosylation in the
Golgi the prorenin molecule is targeted to secretory granules for
storage and release by regulative degranulation by an unknown
mechanism [154]. It was also proposed that the unprocessed
prorenin molecule emerging from trans-Golgi budding is re-
leased directly by constitutive vesiculation of immature Golgi
transport vesicles [23], although a mechanism for the diversion
to this default pathway has not been proposed. The constitutive
vesiculation pathway was suggested to be prevalent in hyper-
tension-induced renal disease [231. Thus, sites of production
and targeting may play a role in LRS, but equally significant are
sites of processing and secretion.
Fig. 6. Renin Content from partially purified subfraCtions of juxtaglo-
merular Cells from three rodent models of low renin syndrome (LRS).
All LRS kidneys were removed from rats with low plasma renin activity
and renin secretory hyporesponsiveness to acute stimulation. All values
are mean 5EM of renin specific activities after subfractionation (*P <
0.05; * < 0.01) [24].
Several additional mechanisms in terms of processing and
secretion may be proposed to explain the low PRA, high plasma
prorenin activity, and renin secretory hyporesponsivity in dia-
betes and other models of LRS. The first is that JG cells from
renin hyporesponsive diabetics and other cases of LRS have a
higher Ca than normal. It is generally established that Ca, is a
final intracellular regulator of RS and that Ca is inversely
related to RS [142, 157—161]. Consequently, it is customary to
associate hypersecretion of renin with low Ca and hyposecre-
tion with high Ca1 [162]. Since prorenin secretion has also been
shown to be regulated by Ca1, though not as thoroughly
investigated as renin itself [1631, it may not be unreasonable to
expect that direct measurement of Ca, in JG cells from renin
hyporesponsive kidneys should have higher Ca1 than normal.
Unfortunately, no direct measurements have been reported.
Elevated Ca has been suggested to be characteristic of both
low- and high-renin disorders [164]. Furthermore, hypertensive
Blacks (generally believed to be low-renin) have a significantly
lower Ca than hypertensive Whites (generally believed to be
moderate-to-high-renin), at least in blood cells [165]. Therefore,
a generalized elevated Ca1 in cells may not account for the renin
hyporesponsivity.
The second proposal for the low PRA in renin hyporespon-
sive diabetics and other cases of LRS is secretory incompe-
tence of stored protein rather than decreased storage. It is
widely believed that decreased total renin content is responsible
for the low PRA and secretory hyporesponsiveness [3]. In
rodent models of diabetes mellitus renin content has been
observed to be significantly elevated [19], thereby providing
evidence against the renin depletion hypothesis. Figure 6 sum-
marizes additional evidence for elevated renal renin content in
diabetic rats and other cases of LRS where renal renin content
is elevated substantially. Thus, although reduced renal renin
content may account for the secretory impairment seen in
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Fig. 7. Subcellular particulate renin distribution in ER and Golgi
transport vesicles (A), mature secretory granules (B), and plasma
membrane vesicles and light microsomes (C) in there rodent models of
low renin syndrome (LRS). All LRS kidneys were removed from rats
with low plasma renin activity and renin secretory hyporesponsiveness
to acute stimulation. All values are mean SEM of renin specific
activities after subfractionation (*P < 0.05; < 0.01) [241.
chronic salt loading [18] and mineralocorticoid excess [20],
reduced content is not a generalized feature of LRS.
The third mechanism responsible for the low PRA and renin
secretory hyporesponsivity is abnormal subcellular redistribu-
tion to divert the protein from the established regulative degran-
ulation secretory pathway. Figure 7 summarizes a recent dem-
onstration of subcellular renin profiles in pituitary deficiency
(surgical), diabetes mellitus (congenital), and thyroid deficiency
(surgical). ER and Golgi transport vesicles, mature secretory
granules, and plasma membrane vesicles and light microsomes
stored 13%, 72%, and 15%, respectively, of the particulate
renin specific activity in JG cells from normal (control) rats.
Whereas the 15% and 13% are substantially higher than what is
expected from studies of other secretory proteins, the 72% in
vesicles and granules is substantially lower than what is ex-
pected for either regulative degranulation [1661 or constitutive
vesiculation [167]. All three models of experimental LRS dem-
onstrate significantly increased renin content in all subcellular
compartments and an associated low rate of secretion, suggest-
ing significant impairment in these models of renin disorder [41.
In pituitary deficiency the unusually large renin presence in
transport vesicles and light microsomes associated with the
plasma membrane subfraction suggests that this site may be a
"sink" for renin destined for export through the regulative
degranulation pathway [13]. In the granular subfraction, despite
the 35-fold increase in renin specific activity over control,
pituitary deficient rats secreted an amount indistinguishable
from controls [11—131. In congenital diabetes mellitus the trans-
port vesicles and light microsomes in the plasma membrane
subfraction appear to be the key sites of storage (Fig. 7). In
thyroid deficiency, on the other hand, ER and Golgi transport
vesicles and mature secretory granules appear to be the major
sites of storage (Fig. 7). Thus, in all three cases of LRS,
abnormal subcellular redistribution of renin away from the
established regulative degranulation secretory pathway may
account for at least some aspects of the secretory impairment.
In humans where there have been demonstrated both racial-
and disease-related differences in PRA, recent studies have
identified a subcellular basis of these differences [22]. Blacks, it
is well recognized, are classified as "low-renin" because of
their lower PRA and secretory hyporesponsivity [24]. Although
JG cells from Blacks store considerable amounts of renin, the
absolute levels are statistically significantly lower than Whites,
and this may in part account for the differences in PRA [1681. In
terms of total cellular renin, however, Blacks and Whites store
similar amounts, but whereas Blacks store a major fraction of
total as prorenin in mature secretory granules, Whites store
their major fraction in ER and Golgi transport vesicles and
heavy microsomes displaced from identifiable mature secretory
granules [22]. In addition, Blacks store an unusually large
proportion of total cellular renin in transport vesicles and light
microsomes of the plasma membrane subfraction. Since consti-
tutive vesiculation may also originate from this site [169], it may
account in part for the excess prorenin secretion in Blacks
[170]. A fair number of diabetic hypertensives, it has been
suggested, may also be classified as renin impaired, and the
cellular basis of the impairment was postulated to be reduced
JG cell renin storage, without consideration of prorenin [31.
Elevated prorenin is a common observation in human diabetes
[1531 and one explanation for the excess secretion of prorenin
may be the excess prorenin presence in JG cells. The major
fraction of subcellular prorenin was localized to the ER and
Golgi transport vesicles and heavy microsomes, suggesting a
constitutive vesiculation secretory pathway similar to that
proposed for prorenin in the renal ischemia [23].
The fourth proposal for the renin secretory impairment is
dysfunction of chemiosmotic components in the secretory
granule. It has been shown that renin secretory granules have a
number of chemiosmotic components (molecules involved in
coordinated chemiosmotic transport of ions and water) that are
required for assistance to complete processing of prorenin to
renin and for engagement to the initial swelling events of
exocytosis [21]. The two shown to be most significant are a
proton ATPase and a KCI-H exchanger translocator [21]. A
proton ATPase was shown to be required to maintain the
intragranular matrix at pH 5.56 0.04 [21]. Acidic pH in the
range of pH 5 to 6 may be required for maximal prorenin
convertase(s) activity [171, 172]. Under normal conditions in
isolated granules from animal models, it was observed that
hypokalemia and/or hypochioremia were inhibitory to renin
release. It was also observed that both hyperkalemia and
hyperchloremia were stimulatory but the effect was sharply
dependent on the acid-base status [21]. Between cytosolic pH 6
to 7 hyperkalemia and hyperchioremia were without effect,
whereas at both acidic and alkalotic pHs renin release from
granules was stimulated by hyperkalemia and hyperchloremia
[21]. It was postulated that at acidic pHs the proton ATPase in
the granular membrane is the primary chemiosmotic component
A ER and Golgi transport vesicles
B Mature seretory vesicles and granules. .
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responsible for inward proton translocation to acidify the gran-
ular matrix and activate prorenin convertase(s) to process
prorenin to renin. Impairment in the proton ATPase activity or
cytosolic alkalinity would consequently prevent inward proton
pumping and inactivation of the convertase(s) thereby yielding
a decreased intragranular renin activity [21]. It was also shown
that at alkaline pHs the KC1-H exchanger in the granular
membrane is the primary chemiosmotic component responsible
for granular swelling and exocytotic release of granular content
[21]. Impairment in the KC1-H exchanger would consequently
promote increased granular storage of renin and prorenin
without secretion. Thus, the fourth proposal is that an impair-
ment in the proton ATPase in the granular membrane leads to
impaired prorenin processing and an impairment in the KCI-H
exchanger leads to incompetence in RS. Several lines of evi-
dence support this hypothesis [4]. Biochemical characterization
of these molecules are now required.
The final mechanism which may partly explain the low PRA
and secretory hyporesponsivity in some renin hyporesponsive
disorders is impairment in export at the level of light mi-
crosomes and plasma membrane. A renin anchorage system has
long been recognized in the plasma membrane of JG cells [13,
173, 174]. Renin is cleavage from the anchorage system by
trypsin, melittin, kallikrein, phospholipase A2, lysolecithin, and
high salt. Ca and Ba increase cleavage, whereas Mg and Mn
decrease it. Translocation is stimulated by calmodulin (in the
absence of Ca) and KC1, and inhibited by La [4]. In models of
renin disorder stimulation of secretion not infrequently leads to
increased renin trapping in the transport vesicles and light
microsomes of the plasma membrane subfraction and to de-
creased export to the extracellular space [13]. Furthermore, in
animal models of diabetes the major fraction of cellular renin
was observed in light microsomal fraction containing plasma
membrane transport vesicles (Fig. 7), suggesting that a dysfunc-
tion in the plasma membrane and light microsomes subfraction
of JG cell may play a significant role in the renin secretory
hyporesponsivity.
Summary and outlook
It is generally accepted that RAAS plays an important role in
(patho)physiology (physiology with imminent pathophysiology)
of cardiovascular and renal regulation. The classical barorecep-
tor, neurogenic, hormonal, and macula densa mechanisms
regulate renin expression at the cellular level by Ca, cAMP, and
chemiosmotic forces. The baroreceptor mechanism operates
through Ca1 as a second messenger which activates K and Cl
channels in the surface membrane and deactivates a KCI-H
exchange transporter in the secretory granular membrane. The
neurogenic mechanism, partly through modulating Ca1, but
mostly by stimulating the generation of cAMP as a second
messenger, plays an important role both in enhancing transcrip-
tion and in stimulating RS. Hormones and neurohormones
affect either Ca or cAMP pathways. The macula densa mecha-
nism involves the processing of prorenin to renin for subse-
quent secretion by a chemiosmotic mechanism. This role of the
macula densa and its unique anatomical juxtaposition with the
juxtaglomerular cell may explain the diversity of plasma prore-
nm presence in mammals. Allometric analysis shows that
animal size correlates directly with plasma prorenin levels, and
those levels of prorenin correlate positively with GFR and
nephron size, and chemiosmotic flux at the macula densa. The
macula densa therefore plays an important role in differential
release of renin and prorenin in response to physiological
challenges and pathophysiological conditions by virtue of its
control of chemiosmotic flux.
Analysis of a few clinical disorders suggest one striking
similarity: suppressed RS. In an attempt to observe further the
(patho)physiological mechanisms of this secretory hyporespon-
sivity, a broader picture of several renin disorders have
emerged which when probed at the subcellular level reveals a
multiplicity of impairment sites; the following is a representa-
tive example of the foregoing discussion. First, low PRA
signifies an impairment in renin production and secretion which
results from abnormal JG cell secretory expression and not
from extrarenal factors. Second, although there may be a slight
impairment in signal transduction at the plasma membrane in
diabetes mellitus with neuropathy and perhaps in some cases of
hypertension, the more pronounced impairment(s) is at the
intracellular level downstream from the generation of Ca1 as an
intracellular messenger.
Third, reduced cellular renin content is not entirely respon-
sible for the low PRA in all cases of LRS because in both
congenital diabetes in rodents and in human non-insulin-depen-
dent diabetic hypertension as well as in other cases of LRS,
such as pituitary deficiency and thyroid insufficiency, renal
renin content is significantly elevated. It should be noted,
however, that reduced renin production (and therefore subnor-
mal storage) may be significant in cases such as primary
aldosteronism and chronic salt excess, where suppression may
be at the level of translation and transcription.
Fourth, impairments may be localized at various intracellular
sites along the secretory pathway—ER and Golgi transport
vesicles, mature secretory granules, and plasma membrane—as
evidenced by subcellular fractionation studies. Reduced traf-
ficking from ER and Golgi network to mature secretory gran-
ules may be a feature of cases such as diabetes and thyroid
hypofunction, where renin storage appears high in these com-
partments and where the primary mode of secretion appears to
be constitutive vesiculation of prorenin. Reduced release from
mature secretory granules may be a feature of cases such as
thyroid insufficiency and pituitary deficiency where granular
content is in excess of normal but secretion is impaired.
Fifth, prorenin is the predominant species secreted in most
cases of LRS, including diabetes and diabetic hypertension.
The unusually large fraction of prorenin demonstrated at vari-
ous sites along the secretory pathway suggests that incomplete
processing of the precursor molecule may be one reason for the
lower active renin appearing in plasma.
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